Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Código QR

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia

Initial induction chemotherapy to eradicate the bulk of acute myeloid leukemia (AML) cells results in complete remission (CR) in the majority of patients. However, leukemic cells persisting in the bone marrow below the morphologic threshold remain unaffected and have the potential to proliferate and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	acute myeloid leukemia minimal/measurable residual disease MRD next generation sequencing clonal hematopoiesis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/402b4a3efadf49d3a4213abadf25d0bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The genetic analysis of Chinese patients with clonal cytopenias using targeted next-generation sequencing
por: Lijuan Zhang, et al.
Publicado: (2021)

Strategies for minimal residual disease detection: current perspectives
por: Andreani G, et al.
Publicado: (2019)

Detection and monitoring of minimal residual disease in acute megakaryoblastic leukemia in children
por: Alexandra D. Palladina, et al.
Publicado: (2021)

Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?
por: Pietro Merli, et al.
Publicado: (2021)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Brittany M. Smith, et al.
Publicado: (2021)

Tratamiento de la leucemia mieloblástica aguda con translocación (8;21) en Hospital Base Valdivia: ejemplificado en un caso clínico
por: Salinas-Laval,José, et al.
Publicado: (2021)

Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
por: Shakeri S., et al.
Publicado: (2021)

IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells
por: Zhang,Feng, et al.
Publicado: (2019)

Myeloid sarcoma: an uncommon presentation of myeloid neoplasms; a case series of 4 rare cases reported in a tertiary care institute
por: Toyaja Jadhav, et al.
Publicado: (2021)

TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137
por: Wang Sheng, et al.
Publicado: (2020)

Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia
por: Briot T, et al.
Publicado: (2017)

CHRONIC MYELOID LEUKEMIA - CLINICAL AND IMMUNOLOGICAL PECULIARITIES IN ADULT PATIENTS
por: O. V. Smirnova
Publicado: (2012)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou T, et al.
Publicado: (2017)

Acute myeloid leukemia with leukemic pleural effusion and high levels of pleural adenosine deaminase: A case report and review of literature
por: Wang Sing-Ting, et al.
Publicado: (2021)

Database-Guided Analysis for Immunophenotypic Diagnosis and Follow-Up of Acute Myeloid Leukemia With Recurrent Genetic Abnormalities
por: Carmen-Mariana Aanei, et al.
Publicado: (2021)

Concurrent Onset of Chronic Lymphocytic Leukemia and Atypical Phenotype Acute Myeloid Leukemia Revealed by Autopsy
por: Sayaka Kiso, et al.
Publicado: (2021)

Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy
por: Petrushev B, et al.
Publicado: (2016)

Circular RNAs in acute myeloid leukemia
por: Vijendra Singh, et al.
Publicado: (2021)

The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia
por: Romeo Gabriel Mihaila, et al.
Publicado: (2021)

Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database
por: Lucia Gozzo, et al.
Publicado: (2021)

METABOLIC STATE OF BLOOD LYMPHOCYTES IN CHRONIC MYELOID LEUKEMIA AND CHRONIC LYMPHOID LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014)

Leucemia promielocítica aguda: Resultados del protocolo terapéutico LPA2000, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile
por: Undurraga,María Soledad, et al.
Publicado: (2013)

Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species
por: Dou J, et al.
Publicado: (2021)

The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
por: Débora Bifano Pimenta, et al.
Publicado: (2021)

A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia
por: Seyed Mohammadreza Bolandi, et al.
Publicado: (2021)

Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML
por: Sonia Jaramillo, et al.
Publicado: (2021)

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
por: Stemer G, et al.
Publicado: (2021)

NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway
por: Chaoqin Zhong, et al.
Publicado: (2021)

LINC00998 functions as a novel tumor suppressor in acute myeloid leukemia via regulating the ZFP36 ring finger protein/mammalian target of rapamycin complex 2 axis
por: Ximin Fang, et al.
Publicado: (2021)

Corrigendum: NLRP3 Inflammasome Promotes the Progression of Acute Myeloid Leukemia via IL-1β Pathway
por: Chaoqin Zhong, et al.
Publicado: (2021)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
por: Ayşe Hilal Eroğlu Küçükdiler, et al.
Publicado: (2021)

Resultados en el tratamiento de pacientes con leucemia mieloide aguda no promielocítica en el Hospital Clínico de la Pontificia Universidad Católica entre los años 2010-2014
por: Fuentes,Mónica, et al.
Publicado: (2015)

Leucemia mieloide aguda secundaria a inmunosupresores en una paciente trasplantada de pulmón, una inusual y letal entidad
por: Peña,Camila, et al.
Publicado: (2015)

Impact of Perioperative Absolute Neutrophil Count on Central Line-Associated Bloodstream Infection in Children With Acute Lymphoblastic and Myeloid Leukemia
por: Illya Martynov, et al.
Publicado: (2021)

The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies
por: Mojdeh Soltani, et al.
Publicado: (2021)

Leucemia mieloide aguda del adulto: Resultados del Protocolo Nacional de Drogas Antineoplásica. Hospital del Salvador 1990-1998
por: Puga L,Barbara, et al.
Publicado: (2000)

Structure-Activity Relationship of Hydroxycinnamic Acid Derivatives for Cooperating with Carnosic Acid and Calcitriol in Acute Myeloid Leukemia Cells
por: Aviram Trachtenberg, et al.
Publicado: (2021)

Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
por: Kyoko Ito, et al.
Publicado: (2021)

Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance
por: Sylvain Garciaz, et al.
Publicado: (2021)

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Yan Peng, et al.
Publicado: (2021)